Q2 FY26 · Ended Jun 27, 2026 · View SEC filing
Selling CDMO left the smallest segment the most profitable
Manufacturing brings in 18.7% of revenue but 29.0% of segment profit, a shift the filing credits to the CDMO sale.
For investorsWhat the cleaner margin depends on after the sales
For foundersOwning the step a regulator requires
The segments earned $226.3M, but unallocated corporate costs, swollen by deal and efficiency work, left $119.9M of operating income.
Operating income rose 19.7%, yet a divestiture loss and the tax effects of the sales left shareholders with a net loss.
Free cash flow reached 14.8% of revenue in a loss-making quarter, repeating last year's split between cash and reported profit.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Charles River Laboratories from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
